© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
September 19, 2008
In a separate analysis of patients enrolled in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, thin patients and those with moderate-to-severe obesity were at increased risk for cardiovascular events. These results indicate that patients at the low anda high ends of the body size spectrum should be treated aggressively to lower the risk of cardiovascular events.
Karan Lal, DO: Eczema Awareness Month and FDA Approval of Dupilumab
High Melanoma Incidence Associated with Diagnostic Scrutiny Rather Than UV Exposure
Robert Cionni, MD: Innovations in Drug Delivery for Glaucoma Treatment